BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine
BioRestorative Therapies (NASDAQ:BRTX) announced that its Chief Scientist and VP of R&D, Francisco Silva, has been appointed Section Editor of the new Regenerative Medicine section in the Journal of Translational Medicine. This prestigious journal ranks among the top 3% worldwide with a 2021 impact factor of 8.440. Silva, who leads BRTX's cell-based therapeutics development, is currently the principal investigator for a Phase 2 study of BRTX-100 in treating chronic lumbar disc disease. He also pioneered the development of an artificial 3D brown adipose transplant using human brown adipose stem cells for the company's ThermoStem® program. Silva's appointment highlights BRTX's growing prominence in regenerative medicine research and development.
BioRestorative Therapies (NASDAQ:BRTX) ha annunciato che il suo Chief Scientist e VP di R&D, Francisco Silva, è stato nominato Section Editor della nuova sezione di Medicina Rigenerativa nel Journal of Translational Medicine. Questa prestigiosa rivista si colloca tra il 3% delle migliori a livello mondiale, con un fattore di impatto di 8,440 nel 2021. Silva, che guida lo sviluppo delle terapie cellulari di BRTX, è attualmente il ricercatore principale per uno studio di Fase 2 su BRTX-100 per il trattamento della malattia discale lombare cronica. Ha anche pionierato lo sviluppo di un trapianto artificiale di tessuto adiposo marrone 3D utilizzando cellule staminali adipose marroni umane per il programma ThermoStem® dell'azienda. La nomina di Silva evidenzia la crescente importanza di BRTX nella ricerca e nello sviluppo della medicina rigenerativa.
BioRestorative Therapies (NASDAQ:BRTX) anunció que su Científico Jefe y VP de I+D, Francisco Silva, ha sido nombrado Editor de Sección de la nueva sección de Medicina Regenerativa en el Journal of Translational Medicine. Esta prestigiosa revista se encuentra entre el 3% de las mejores a nivel mundial, con un factor de impacto de 8.440 en 2021. Silva, quien lidera el desarrollo de terapias basadas en células de BRTX, es actualmente el investigador principal de un estudio de Fase 2 sobre BRTX-100 para tratar la enfermedad discal lumbar crónica. También fue pionero en el desarrollo de un trasplante artificial de tejido adiposo marrón en 3D utilizando células madre de tejido adiposo marrón humano para el programa ThermoStem® de la empresa. El nombramiento de Silva destaca la creciente relevancia de BRTX en la investigación y desarrollo de la medicina regenerativa.
바이오레스토라티브 테라피스(BioRestorative Therapies) (NASDAQ:BRTX)는 최고 과학자이자 연구개발(VP of R&D)인 프란시스코 실바(Francisco Silva)가 저널 오브 트랜슬레이셔널 메디슨(Journal of Translational Medicine)의 새로운 재생 의학 섹션의 섹션 편집자로 임명됐음을 발표했습니다. 이 저명한 저널은 2021년 임팩트 팩터가 8.440으로 전 세계 상위 3%에 속합니다. 실바는 BRTX의 세포 기반 치료 개발을 이끌고 있으며 현재 만성 요추 디스크 질환 치료를 위한 BRTX-100의 제2상 연구의 주 연구자입니다. 그는 또한 회사의 ThermoStem® 프로그램을 위해 인간 갈색 지방 줄기세포를 사용하여 인공 3D 갈색 지방 이식을 개발한 선도적인 인물입니다. 실바의 임명은 재생 의학 연구 및 개발에서 BRTX의 증가하는 중요성을 강조합니다.
BioRestorative Therapies (NASDAQ:BRTX) a annoncé que son scientifique en chef et VP de la R&D, Francisco Silva, a été nommé rédacteur de section de la nouvelle section Médecine régénérative dans le Journal of Translational Medicine. Ce prestigieux journal figure parmi les 3 % des meilleures publications au monde, avec un facteur d'impact de 8,440 en 2021. Silva, qui dirige le développement des thérapies cellulaires de BRTX, est actuellement l'investigateur principal d'une étude de Phase 2 sur BRTX-100 pour le traitement de la maladie discale lombaire chronique. Il a également été pionnier dans le développement d'un greffon de graisse brune 3D artificiel utilisant des cellules souches adipeuses brunes humaines pour le programme ThermoStem® de l'entreprise. La nomination de Silva met en lumière l'importance croissante de BRTX dans la recherche et le développement de la médecine régénérative.
BioRestorative Therapies (NASDAQ:BRTX) gab bekannt, dass Francisco Silva, Chief Scientist und VP für F&E, als Abschnittsredakteur für den neuen Bereich Regenerative Medizin im Journal of Translational Medicine ernannt wurde. Diese angesehene Zeitschrift zählt zu den besten 3 % weltweit und hatte 2021 einen Impact-Faktor von 8,440. Silva, der die Entwicklung von zellbasierten Therapeutika bei BRTX leitet, ist derzeit der Hauptforscher einer Phase-2-Studie zu BRTX-100 zur Behandlung von chronischen lumbalen Bandscheibenerkrankungen. Zudem war er der Pionier bei der Entwicklung eines künstlichen 3D-Transplantats aus braunem Fettgewebe mit menschlichen braunen Fettstammzellen für das ThermoStem®-Programm des Unternehmens. Silvas Ernennung unterstreicht die wachsende Bedeutung von BRTX in der Forschung und Entwicklung der regenerativen Medizin.
- Appointment of Chief Scientist as Section Editor in prestigious journal enhances company's credibility
- Ongoing Phase 2 study of BRTX-100 for chronic lumbar disc disease
- Development of novel ThermoStem® program for metabolic diseases
- None.
- New journal section will focus on emerging and translation work in the field of regenerative medicine -
MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, is pleased to announce that its Chief Scientist and Vice President of Research and Development, Francisco Silva, has been named Section Editor of the newly launched Regenerative Medicine section of the Journal of Translational Medicine.
The Journal of Translational Medicine is a peer-reviewed open-access medical journal which has been published since 2003. According to the Journal Citation Reports, the journal had a 2021 impact factor of 8.440, ranking it among the top
"We are excited to expand the journal’s focus on regenerative medicine and are thrilled to have found someone with Francisco’s demonstrated research excellence, pioneering clinical experience, and ability to serve as a respected ambassador to become our newest Section Editor,” said the Journal of Translational Medicine’s Editor-in-Chief, Francesco Marincola, MD.
Mr. Silva has extensive experience in developing and translating cell-based therapeutics. At BioRestorative, he leads a team of scientists developing cell-based therapeutics targeting musculoskeletal and metabolic disorders. Currently, he is the principal investigator of an ongoing Phase 2 study investigating the use of BRTX-100, the Company’s lead cell therapy clinical-stage candidate, in treating chronic lumbar disc disease (cLDD). More recently, Mr. Silva began developing BioRestorative’s novel allogeneic, off-the-shelf ThermoStem® metabolic disease program. Through that work, he was the first to develop an artificial 3D brown adipose transplant using human brown adipose stem cells.
Earlier in his career, in 2008, Mr. Silva was one of the first to publish on the use of stem cells in patients suffering from spinal cord injury. In addition, his research has led to the discovery of novel cell types isolated from umbilical cord, bone marrow and adipose tissue. He has authored several peer-reviewed papers focused on regenerative medicine, and has been issued numerous U.S. and international patents in the field. Mr. Silva earned a degree in Biology from California State Polytechnic University, where he also obtained a Graduate Presidential Fellowship and a Minority Biomedical Research Support (MBRS) Fellowship.
"I am deeply honored to have been selected to help launch this important new special section of the Journal of Translational Medicine," Mr. Silva said. “Today, most regenerative medicine research remains confined to the bench rather than the bedside. But if our cell-based therapy development progress at BioRestorative, as well as that at several other companies, is any indication, it may not be long before the full clinical potential of the field is realized. I am energized by this unique opportunity to work with my scientific colleagues from around the world to help fulfill that vision.”
About BioRestorative Therapies, Inc.
BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we have also recently begun offering BioCosmeceutical products:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.
• Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.
• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via Investigational New Drug (IND)-enabling studies, with the aim of pioneering U.S. Food and Drug Administration (FDA) approvals in the emerging BioCosmeceuticals space.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com
![](https://ml.globenewswire.com/media/ZjUwZjYzZjItZjNmZS00YTUyLTliODUtZGM3ZDU2MTI5ZDM5LTUwMDA4MDA0MA==/tiny/BioRestorative-Therapies-Inc.png)
FAQ
What is the significance of Francisco Silva's appointment as Section Editor for BRTX?
What are the main clinical programs BRTX is currently developing?